From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?

From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?

Since the outbreak of the COVID-19 pandemic in December 2019, the SARS-CoV-2 genome has undergone several mutations. The emergence of such variants has resulted in multiple pandemic waves, contributing to sustaining to date the number of infections, hospitalisations, and deaths despite the swift dev...

Full description

Bibliographic Details
Main Authors: Matteo Pavan, Davide Bassani, Mattia Sturlese, Stefano Moro
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
SARS-CoV-2
COVID-19
XE variant
XD variant
Spike protein
Mpro
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2022.2081847

Internet

https://www.tandfonline.com/doi/10.1080/14756366.2022.2081847

Similar Items